论文部分内容阅读
To describe outcomes of transcatheter embolotherapy (TCE)-in children with pulmonary arteriovenous malformations (PAVMs). Chart and imaging review of all children (age ≤ 18 years) treated for PAVMs by TCE at three hereditary hemorrhagic telangiectasia centers. All 42 treated patients were included, with a mean age of 12 years (range, 4 to 18). Cyanosis was present in 25 of 42 patients (60% ). Hemoptysis had occurred in 3 of 42 patients (7% ) and neurologic complications (stroke, cerebral abscess) occurred in 8 patients (19% ) before assessment. PAVMs were focal in 30 of 42 (71% ) and diffuse in 12 of 42 (29% ) patients. TCE was performed for 172 PAVMs and 35 diffuse regions (regional TCE). Follow-up was obtained in 38 of 42 (90% ) patients (mean, 7 years). After TCE in patients with focal PAVMs, oxygenation improved significantly, with no further complications from the PAVMs. Reperfusion was noted in 23 of 153 (15% ) PAVMs. Eighteen of 23 (78% ) of these were retreated, with documented aneurysmal involution in 10 of 13 (77% ) patients. TCE complications included pleuritic chest pain (24% of sessions) and deployment complications (device paradoxical embolization or device misplacement) (3% of sessions, 1% of PAVMs), with no long-term complications. PAVMs cause life-threatening complications in children; treatment with TCE is safe, with complication rates comparable to adult rates.
To describe outcomes of transcatheter embolotherapy (TCE) -in children with pulmonary arteriovenous malformations (PAVMs). Chart and imaging review of all children (age ≤ 18 years) treated for PAVMs by TCE at three hereditary hemorrhagic telangiectasia centers. All 42 treated patients were Cyanosis was present in 25 of 42 patients (60%). Hemoptysis occurred in 3 of 42 patients (7%) and neurologic complications (stroke, cerebral abscess ) occurred in 8 patients (19%) before assessment. PAVMs were focal in 30 of 42 (71%) and diffuse in 12 of 42 (29%) patients. TCE was performed for 172 PAVMs and 35 diffuse regions (regional TCE). Follow-up was obtained in 38 of 42 (90%) patients (mean, 7 years). After TCE in patients with focal PAVMs, oxygenation improved significantly, with no further complications from the PAVMs. %) PAVMs. Eighteen of 23 (78%) of these were retreated, with document T ane spending pleuritic chest pain (24% of sessions) and deployment complications (device paradoxical embolization or device misplacement) (3% of sessions, 1% of PAVMs), with no ed aneurysmal involution in 10 of 13 (77% long-term complications. PAVMs cause life-threatening complications in children; treatment with TCE is safe, with complication rates comparable to adult rates.